.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Novartis
Fuji
Mallinckrodt
Merck
Express Scripts
McKesson
Harvard Business School
Teva

Generated: December 12, 2017

DrugPatentWatch Database Preview

Duchesnay Company Profile

« Back to Dashboard

What is the competitive landscape for DUCHESNAY, and what generic alternatives to DUCHESNAY drugs are available?

DUCHESNAY has three approved drugs.

There are twelve US patents protecting DUCHESNAY drugs.

There are one hundred and seventy-four patent family members on DUCHESNAY drugs in fifty-three countries and twelve supplementary protection certificates in ten countries.

Summary for Duchesnay

International Patents:174
US Patents:12
Tradenames:3
Ingredients:2
NDAs:3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
DuchesnayBONJESTAdoxylamine succinate; pyridoxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL209661-001Nov 7, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
DuchesnayDICLEGISdoxylamine succinate; pyridoxine hydrochlorideTABLET, DELAYED RELEASE;ORAL021876-001Apr 8, 2013ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
DuchesnayBONJESTAdoxylamine succinate; pyridoxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL209661-001Nov 7, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
DuchesnayDICLEGISdoxylamine succinate; pyridoxine hydrochlorideTABLET, DELAYED RELEASE;ORAL021876-001Apr 8, 2013ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
DuchesnayBONJESTAdoxylamine succinate; pyridoxine hydrochlorideTABLET, EXTENDED RELEASE;ORAL209661-001Nov 7, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
DuchesnayOSPHENAospemifeneTABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DUCHESNAY drugs

Drugname Dosage Strength Tradename Submissiondate
doxylamine succinate and pyridoxine hydrochlorideDelayed-release Tablets10 mg/10 mgDICLEGIS8/1/2013

Non-Orange Book Patents for Duchesnay

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,984,665Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Duchesnay Drugs

Country Document Number Estimated Expiration
Japan2007522190► Subscribe
Australia2001272243► Subscribe
TaiwanI595874► Subscribe
Norway20151603► Subscribe
Brazil0112659► Subscribe
Ukraine74807► Subscribe
World Intellectual Property Organization (WIPO)2004004694► Subscribe
Uruguay34631► Subscribe
LithuaniaC1713458► Subscribe
Hungary0301791► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Duchesnay Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00031Denmark► SubscribePRODUCT NAME: OSPEMIFENE OR A GEOMETRIC ISOMER THEREOF, A STEREOISOMER THEREOF, A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AN ESTER THEREOF OR A METABOLITE THEREOF; REG. NO/DATE: EU/1/14/978/001-002 20150115
00742Netherlands► SubscribePRODUCT NAME: OSPEMIFEEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/14/978 20150115
/2015Austria► SubscribePRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150119
736Luxembourg► SubscribePRODUCT NAME: OSPEMIFENE DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION: 20150115
2015023,C1713458Lithuania► SubscribePRODUCT NAME: OSPEMIFENAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/978/001, 2015 01 15 EU/1/14/978/002 20150115
2015 00031Denmark► SubscribePRODUCT NAME: OSPEMIFENE; REG. NO/DATE: EU/1/14/978/001-002 20150115
2015023Lithuania► SubscribePRODUCT NAME: OSPEMIFENUM; REGISTRATION NO/DATE: EU/1/14/978/001, 2015 01 15 EU/1/14/978/002 20150115
6 5010-2015Slovakia► SubscribePRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978 20150119
0150029 00165Estonia► SubscribePRODUCT NAME: OSPEMIFEEN;REG NO/DATE: EU/1/14/978 19.01.2015
15/031Ireland► SubscribePRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Covington
Federal Trade Commission
McKesson
Colorcon
Harvard Business School
Queensland Health
Johnson and Johnson
Novartis
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot